Information Provided By: 
Fly News Breaks for October 1, 2018
AVEO
Oct 1, 2018 | 10:22 EDT
After an Independent Steering Committee recommended the initiation of top-line analysis of Aveo Pharmaceuticals' Phase 3 TIVO-3 trial of tivozanib in third-line renal cell carcinoma, Piper Jaffray analyst Edward Tenthoff noted that the lower than expected event rate of 242 events "minimally reduces" powering of the trial to 88% from the originally planned for 90%, but he remains confident in positive top-line TIVO-3 data being reported in about 6 weeks. Tenthoff reiterates his Overweight rating and $5 price target on Aveo shares.
News For AVEO From the Last 2 Days
There are no results for your query AVEO
